Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 219

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 219
---
quate additional financing may not be available to the Company on acceptable terms, or at all. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the terms of these equity securities or this debt may restrict the Company’s ability to operate. Any future debt financing and equity financing, if available, may involve covenants limiting and restricting the ability to take specific actions, such as incurring additional debt, making capital expenditures, entering into profit-sharing or other arrangements or declaring dividends. If the Company raises additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, it may be required to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to the Company. If the Company is unable to raise capital when needed or on acceptable terms, the Company could be forced to delay, reduce or eliminate its R&D programs or future commercialization efforts. Cash Flows Nine Months Ended September 30, 2024 and 2023

|                                                      |     | For the nine months ended 
 September 30,             
 2024                      |                              (Pro 
 forma, Predecessor and Successor) |   |     |   |          2023 
 (Predecessor) |   |     |   | Difference |   |
|:-----------------------------------------------------|:----|:--------------------------|----------------------------------:|:--|:----|:--|--------------:|:--|:----|:--|-----------:|:--|
| Net cash used in operating activities                |     | $                         |                       (11,375,873 | ) |     | $ |    (4,829,217 | ) |     | $ | (6,546,656 | ) |
| Net cash provided by financing activities:           |     |                           |                        12,240,682 |   |     |   |       571,679 |   |     |   | 11,669,003 |   |
| Net increase (decrease) in cash and cash equivalents |     | $                         |                           864,809 |   |     | $ |    (4,257,539 | ) |     | $ |  5,122,347 |   |

Net cash used in operating activities Net cash used in operating activities increased $6.6 million from $4.8 million to $11.4 million in the nine-month period ended September